4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ascendis Pharma A/S (ASND) operates in the Biotechnology industry and is headquartered in Hellerup, Denmark with about 1,189 employees. Its market capitalization is roughly $17 billion. In the fiscal year ended 2025-12-31, ASND reported $720M in revenue and ($228M) in net income.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Interactive charts & full statements → Open the ASND valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $720M | $364M | $267M | $51M |
| Gross Profit | $625M | $319M | $222M | $39M |
| Operating Income (EBIT) | ($136M) | ($279M) | ($456M) | ($562M) |
| Net Income | ($228M) | ($378M) | ($481M) | ($583M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $247M | $248M | $214M | $158M | $101M | — |
| Gross Profit | $229M | $224M | $191M | $127M | $83M | — |
| Operating Income (EBIT) | $25M | $6M | $11M | ($53M) | ($104M) | — |
| Net Income | $629M | ($34M) | ($61M) | ($39M) | ($95M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.2B | $826M | $1.1B | — |
| Total Liabilities | $1.5B | $1.3B | $971M | $826M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ASND viewer.
About TickerBase · Data methodology & sources